(Dinutuximab)Biosimilar Reference Antibody-GS40183

货号：GS40183

Dinutuximab is a chimeric monoclonal antibody approved for the treatment of high-risk neuroblastoma in pediatric patients. Marketed under the brand name Unituxin®, it is used as part of a multimodality regimen, including surgery, chemotherapy, and radiation, for children who have achieved at least a partial response to prior first-line therapy. Dinutuximab targets a specific antigen expressed on neuroblastoma cells and is administered via intravenous infusion. Its use is associated with significant side effects, including severe pain, capillary leak syndrome, and hypotension, requiring careful supportive management.